AK117 plus azacitidine and venetoclax for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called AK117 combined with two standard AML medicines (azacitidine and venetoclax) for people with acute myeloid leukemia who haven't had certain prior treatments. The goal is to see if this combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia (AML) not caused by certain genetic changes like t(8;21) or t(15;17).
- You have not had leukemia that has spread to your brain or spinal fluid.
- You have not been treated before with venetoclax, azacitidine, decitabine, or a stem cell transplant.
- You are healthy enough for daily activities (ECOG score 0-3, and 0-2 if 75 or older).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Hear when a new ACUTE MYELOID LEUKEMIA; AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.